Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Syntho Pharmaceuticals, Inc.
WARNING LETTER
•Syntho Pharmaceuticals, Inc.•September 10, 2015

Syntho Pharmaceuticals, Inc. – FDA Warning Letter, Sep 10, 2015

Record Details

This FDA Warning Letter, WL: GDUFA-15-020, dated June 22, 2015, was issued to Syntho Pharmaceuticals Inc. for failing to pay required facility fees under the Generic Drug User Fee Amendments of 2012 (GDUFA). The facility, identified in pending and/or approved generic drug submissions, failed to self-identify and pay annual facility fees for fiscal years 2013, 2014, and 2015.

According to GDUFA, a facility engaged in manufacturing or processing active pharmaceutical ingredients or finished dosage forms, and identified in a generic drug submission, must self-identify annually and pay an annual facility fee. Syntho Pharmaceuticals, Inc. did not meet these requirements for the specified fiscal years.

As a result, all drugs or active pharmaceutical ingredients manufactured, prepared, propagated, compounded, or processed at the facility are considered misbranded under 21 U.S.C. §§ 352(aa), 379j-42(g)(4)(A)(iii). Shipping misbranded products in interstate commerce, including importation, is a violation of federal law (21 U.S.C. § 331(a)), potentially leading to injunctions, seizures, or denial of entry into the U.S.

The facility has been placed on a publicly available GDUFA facility arrears list.

Company
Syntho Pharmaceuticals, Inc.
Inspection date
September 10, 2015
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Michael M. Levy
View Company Profile

ID · 6215bed6-0625-4496-af37-ccdc076f22bd

Violation Codes10
21 U.S.C. 379j-4121 U.S.C. 379j-4221 U.S.C. 379j-41(5)(A)(i)21 U.S.C. 379j-42(f)21 U.S.C. 379j-42(a)(4)21 U.S.C. 379j-42(l)21 U.S.C. 352(aa)21 U.S.C. 379j-42(g)(4)(A)(iii)21 U.S.C. 33221 U.S.C. 334

Full citation text and observation details available on the Dashboard.

Other documents for Syntho Pharmaceuticals, Inc.
  • 483 - 2024-03-01March 1, 2024
  • 483 - 2019-09-03September 3, 2019

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Syntho Pharmaceuticals, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.